NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the H&N, and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding evaluation and treatment of nasopharyngeal carcinoma.

[1]  Ying Sun,et al.  Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Brian O'Sullivan,et al.  International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Chiun Hsu,et al.  Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Jimeno,et al.  Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Ji-Jin Yao,et al.  Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? , 2017, Journal of Cancer.

[6]  Ying Sun,et al.  Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  P. Hansasuta,et al.  Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma , 2017, Journal of radiation research.

[8]  George Fountzilas,et al.  What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Liang,et al.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. , 2016, The Lancet. Oncology.

[10]  Jianji Pan,et al.  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial , 2016, The Lancet.

[11]  D. Yeung,et al.  Outcomes of Sinonasal Cancer Treated With Proton Therapy. , 2016, International journal of radiation oncology, biology, physics.

[12]  T. Jovanović,et al.  Characterization of the Variability of Epstein-Barr Virus Genes in Nasopharyngeal Biopsies: Potential Predictors for Carcinoma Progression , 2016, PloS one.

[13]  J. W. Lam,et al.  Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma. , 2016, Chinese clinical oncology.

[14]  A. Garden,et al.  Intensity‐modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes , 2016, Head & neck.

[15]  K. Keum,et al.  IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma , 2016, Strahlentherapie und Onkologie.

[16]  Edwin P Hui,et al.  Nasopharyngeal carcinoma , 2016, The Lancet.

[17]  Z. Zeng,et al.  Epstein–Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma , 2016, Clinical and Translational Oncology.

[18]  Ying Sun,et al.  The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[19]  Hung-Ming Wang,et al.  Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. , 2015, Japanese journal of clinical oncology.

[20]  Jun Ma,et al.  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. , 2015, The Lancet. Oncology.

[21]  Ying Sun,et al.  The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal Carcinoma: The Dawn of a New Era? , 2015, Medicine.

[22]  D. Kwong,et al.  Preliminary results of trial NPC‐0501 evaluating the therapeutic gain by changing from concurrent‐adjuvant to induction‐concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally a , 2015, Cancer.

[23]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[24]  Fares Alahdab,et al.  Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. , 2014, The Lancet. Oncology.

[25]  S. Leung,et al.  Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Simion I. Chiosea,et al.  Human papillomavirus and Epstein–Barr virus in nasopharyngeal carcinoma in a low‐incidence population , 2014, Head & neck.

[27]  R. Chernock,et al.  Human Papillomavirus and Epstein Barr Virus in Head and Neck Carcinomas: Suggestions for the New WHO Classification , 2014, Head and Neck Pathology.

[28]  F. Feng,et al.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. , 2014, International journal of radiation oncology, biology, physics.

[29]  T. Delaney,et al.  Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma. , 2013, International journal of radiation oncology, biology, physics.

[30]  M. Robinson,et al.  Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population , 2013, Infectious Agents and Cancer.

[31]  Q. Le,et al.  Results of a phase 2 study examining the effects of omitting elective neck irradiation to nodal levels IV and Vb in patients with N(0-1) nasopharyngeal carcinoma. , 2013, International journal of radiation oncology, biology, physics.

[32]  A. Chi,et al.  Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation , 2013, Journal of Hematology & Oncology.

[33]  Amy Y. Chen,et al.  Head and neck carcinoma in the United States , 2012, Cancer.

[34]  Wen-Qi Jiang,et al.  Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma , 2012, Journal of Cancer Research and Clinical Oncology.

[35]  T. Hashimoto,et al.  Clinical Investigation : Head and Neck Cancer Outcome of T 4 ( International Union Against Cancer Staging System , 7 th edition ) or Recurrent Nasal Cavity and Paranasal Sinus Carcinoma Treated With Proton Beam , 2012 .

[36]  Todd Pawlicki,et al.  An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  Ying Sun,et al.  Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[38]  A. Garden,et al.  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. , 2012, The Lancet. Oncology.

[39]  E. Cohen,et al.  Current Treatment Options for Metastatic Head and Neck Cancer , 2012, Current Treatment Options in Oncology.

[40]  P. Sunpaweravong,et al.  Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil in locally advanced nasopharyngeal carcinoma , 2011, Head & neck oncology.

[41]  D. Pfister,et al.  Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[42]  Xianglin L. Du,et al.  Evaluation of trends in the use of intensity‐modulated radiotherapy for head and neck cancer from 2000 through 2005 , 2010, Cancer.

[43]  R. Kohno,et al.  Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. , 2010, International journal of radiation oncology, biology, physics.

[44]  J. Lambea,et al.  Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment , 2010, British Journal of Cancer.

[45]  J. Hwang,et al.  Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer , 2010, Cancer Chemotherapy and Pharmacology.

[46]  Jin-Ching Lin,et al.  Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma , 2010, Clinical Cancer Research.

[47]  J. Buatti,et al.  Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. , 2009, International journal of radiation oncology, biology, physics.

[48]  F. Hirsch,et al.  Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  W. De Neve,et al.  Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. , 2009, International journal of radiation oncology, biology, physics.

[50]  M. Monzó,et al.  Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients , 2009, Acta oto-laryngologica.

[51]  M. Gulley,et al.  Laboratory assays for Epstein-Barr virus-related disease. , 2008, The Journal of molecular diagnostics : JMD.

[52]  S. Leung,et al.  Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[54]  Jin-Ching Lin,et al.  Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[55]  I. Chitapanarux,et al.  Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. , 2007, European journal of cancer.

[56]  Yang Zhang,et al.  Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy , 2007, Cancer Chemotherapy and Pharmacology.

[57]  D. Gandara,et al.  Evaluation of the Combination of Docetaxel/Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study , 2007, Cancer investigation.

[58]  J. Sham,et al.  Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. , 2006, International journal of radiation oncology, biology, physics.

[59]  H. Adami,et al.  The Enigmatic Epidemiology of Nasopharyngeal Carcinoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[60]  A. Colevas.  Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  W. Mendenhall,et al.  Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  B. Murphy,et al.  Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Whang‐Peng,et al.  Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[66]  J. Blay,et al.  Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. , 2004, European journal of cancer.

[67]  J. Shah,et al.  The role of neck dissection following definitive chemoradiation. , 2004, Oncology.

[68]  C. Kim,et al.  Molecular characterization of epstein‐barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea , 2004, Head & neck.

[69]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[70]  S. Leung,et al.  Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early‐stage nasopharyngeal carcinoma of undifferentiated type , 2003, Cancer.

[71]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Gulley.  Molecular diagnosis of Epstein-Barr virus-related diseases. , 2001, The Journal of molecular diagnostics : JMD.

[73]  D. Neuberg,et al.  Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck , 1998, Cancer.

[74]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  J. Wanamaker.  Radiation therapy for head and neck neoplasms , 1997 .

[76]  A. Garden,et al.  Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. , 1997, International journal of radiation oncology, biology, physics.

[77]  Kathryn Flynn,et al.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. , 1995, The New England journal of medicine.

[78]  M. Piccart,et al.  Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck , 1994 .

[79]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  G. Lyman,et al.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  H. Goepfert.  Radiation Therapy for Head and Neck Neoplasms , 1984 .

[82]  G. Fletcher,et al.  Megavoltage irradiation of epithelial tumors of the nasopharynx. , 1981, International journal of radiation oncology, biology, physics.

[83]  R. Hoppe,et al.  Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy , 1976, Cancer.

[84]  A. Garden,et al.  Controversies in surgical management of the node-positive neck after chemoradiation. , 2009, Seminars in radiation oncology.

[85]  N. Hanna.  Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study , 2007 .

[86]  M. Zelefsky,et al.  Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. , 2006, International journal of radiation oncology, biology, physics.